Biomarker ID | 1185 |
PMID | 23918943 |
Year | 2013 |
Biomarker | Methylation Status of AOX1 (High vs. Low) |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: univariate : [HR = 1.69 ( 95% CI: 1.11-2.58), p-value = 0.015, AUC: 0.60 ]; multivariate : [HR = 1.40 (95% CI: 0.88-2.21) p-value=0.151]Cohort 2: univariate : [HR = 1.732 (95% CI: 0.912-3.287), p-value= 0.093, AUC=0.61] |
Effect on Pathways | Pathways include: Nicotine metabolism, Nitric oxide effects, Vitamin B6 metabolism, Nicotinate and nicotinamide metabolism, Valine, leucine and isoleucine degradation |
Experiment | Biochemical recurrence |
Type of Biomarker | Prognostic |
Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
Senstivity | NA |
Specificity | NA |
AUC | 0.919 |
Accuracy | NA |
Level Of Significance | P < 0.001 |
Method Used | quantitative methylation specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | AOX1 |